Treatment of cancer with kdm4 inhibitors
AssigneesCelgene Corporation, Tachyon Therapeutics, Inc.
InventorsFrank PERABO, Jeffrey A. STAFFORD, Michael CLARKE, Young K. CHEN
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions and methods for the treatment of a cancer. Said compositions comprise a KDM4 inhibitor.
Claims60
A method of treating a cancer in a cancer patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt or a solvate thereof, wherein the compound having the structure:
A method of reducing tumorigenic cell population in cancer a patient in need thereof, comprising administering to the patient therapeutically effective amount of a compound, or a pharmaceutically acceptable salt or a solvate thereof, wherein the compound having the structure:
A method of reducing tumor initiating cell frequency in a cancer patient in need thereof, comprising administering to the patient therapeutically effective amount of a compound, or a pharmaceutically acceptable salt or a solvate thereof, wherein the compound having the structure:
A method of inhibiting cancer stem cells in a cancer patient in need thereof, comprising administering to the patient therapeutically effective amount of a compound, or a pharmaceutically acceptable salt or a solvate thereof, wherein the compound having the structure:
A method of treating a cancer in a cancer patient in need thereof, comprising:
- (a) determining high microsatellite instability (MSI-H) status of the cancer patient, and
- (b) administering therapeutically effective amount of a compound or a pharmaceutically acceptable salt or a solvate thereof to the cancer patient if the cancer patient is determined to be a MSI-H cancer patient, wherein the compound having the structure:
A method of treating cancer, comprising:
- (a) obtaining a sample from a patient having the cancer;
- (b) determining the level of a biomarker in the sample;
- (c) diagnosing the patient as being likely to be responsive to a treatment compound if the level of the biomarker in the sample is different from a reference level of the biomarker;
- and (d) administering a therapeutically effective amount of the treatment compound to the patient;
- and
- wherein the treatment compound is Compound 1, or a pharmaceutically acceptable salt or a solvate thereof;
- and
- the biomarker is PNUTS.
Dependencies are inferred from the claim text.